Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-583-1 | CAS number: 108-44-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
In summary, m-toluidine is assumed to be absorbed following inhalation, oral,
or dermal exposure, readily distributed in the body and metabolized.
Accumulation is not expected. Urinary excretion is assumed to be the
main elimination route.
In addition, due to the lack of acute dermal toxicity data (sec.
exposure route) p-isopropyl aniline was chosen as surrogate to fill the
data gap. Both substances have similar physicochemical properties, are
aromatic amines revealing equal main intrinsic properties as shown by
methemoglobin formation and/or erythrocyte toxicity.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Summary of Justification for Read Across to fill data gaps
m-Toluidine shall be registered according to Art 10 of Regulation EC No. 1907 / 2006 (REACh), for annual production of 100 tonnes (Annex VIII). However, the required toxicological data for information submitted for general registration purposes (Art 10) at this tonnage band are not complete For m-toluidine no reliable data are available for acute dermal toxicity (sec. exposure route).
According to ECHA Document: Guidance on information requirements and chemical safety assessment volume R 6: QSARs and grouping of chemicals (2008) section.2.3 p.: 89 and Practical Guide No. 6 (2012) an accepted method to fill data gaps is by read–across technique. Read across can be performed by different ways. In this case the One-to one approach is chosen. For this approach as analogue molecule p-Isopropyl aniline (CAS-No. 99-88-7) is chosen.
For both substances methemoglobinemia and / or erythrocyte toxicity seems to be the most relevant mechanism for systemic toxicity. Consequently, p-isopropyl aniline and m-toluidine were used as analogue substances in a read-across apporoach to fill the data gaps. This approach is justified because both substances have similar physicochemical properties, are aromatic amines revealing equal main intrinsic properties as shown by methemoglobin formation and/or erythrocyte toxicity.
Summary of Information/assumptions regarding Toxicokinetics, Metabolsim and Distribution
INTRODUCTION
Only limited specific information on toxicokinetic, metabolism or distribution of m-toluidine in animals or in humans is available. Therefore, the following statements on toxicokinetics of m-toluidine are based on the physico-chemical data as well as on the toxicological studies described in the IUCLID database within the REACH process. The criteria outlined in the Reach Guidance on Information Requirements and Chemical Safety Assessment, Chapter R7c. Section R7.12: Guidance on Toxicokinetics, will be applied throughout the statement.
m-Toluidine (3–methyl aniline) is a colourless liquid at room temperature with a molecular mass of 107.16 g/mol. The melting point of m-toluidine is -31°C, the boiling point is about 203 - 204°C at 1013 hPa. The relative density is 0.99 at 25°C and the vapour pressure of m-toluidine is given in IUCLID dataset as 0.2 hPa at 20°C. The log Pow of m-toluidine is 1.4, and the water solubility of m-toluidine is 15000 mg/L at 20°C.
ABSORPTION
Based on the boiling point of about 203-204 °C and a vapour pressure below 0.5 kPa it can be assumed that vapour inhalation is an unlikely route of exposure. However, the log Pow of 1.4 is in the range that is favorable for absorption after inhalation exposure directly across the respiratory tract epithelium by passive diffusion. There are no studies available using inhalation as exposure route to confirm this assumption. However, according to Reach Guidance on Information Requirements and Chemical Safety Assessment, Chapter R7c. Section R7.12: Guidance on Toxicokinetics, it is likely that the substance will also be absorbed if it is inhaled because there are signs of systemic toxicity present in an oral toxicity study. Respective findings are described in the section below.
The physico-chemical characteristics of m-toluidine (readily soluble in water 15 g/l), log Pow of 1.4 and the molecular mass of 107 g/mol are in a range suggestive of absorption from the gastro-intestinal tract subsequent to oral ingestion, with absorption by passive diffusion as the assumed mechanism. This assumption of an oral absorption is confirmed by acute and sub-acute oral toxicity data. In the acute oral study (rat, LD50 922 mg/kg bw; DuPont De Nemours, 1980a) mortality occurred from 700 mg/kg bw onwards with all animals displaying cyanosis and moderate weight loss. Repeated administration of m-toluidine to rats by gavage in doses up to and including 300 mg/kg bw/day for at least 28 days (Japanese Ministry of Health, Labour and Welfare, MHLW, 1995a) resulted in a LOAEL of 30 mg/kg bw/day based on evidence of hemolytic anemia such as marginal pigment deposit and extra-medullary hematopoiesis in the spleen probably caused by hematotoxicity (methemoglobin formation).
Although no acute dermal study yielding a LD50 value, or no repeated dermal application study is available, dermal absorption can be assumed due to the physico-chemical properties of m-toluidine: log Pow of 1.4 favour dermal absorption particularly because water solubility is high (15 g/l) in addition with the low molecular mass of 107 g/mol. This assumption can be agreed because Senczuk and Rucinska. 1984 (cited in UNEP 2003) reported of dermal absorption after application of m-toluidine to the skin of rats evidenced by determination of up to 40 % methemoglobinemia. Hence, the substance is evaluated as only slightly irritating to the skin (DuPont de Nemours 1980b) and m-toluidine caused no sensitization reactions in the LLNA and no systemic intolerance reactions were reported (Vohr 2009).
Furthermore, methemoglobin formation and consequently systemic availability is observed in different acute studies. UNEP 2003 summarizes:
Major reports of methemoglobin formation are shown in Table 1. A single administration of m-toluidine induces severe methemoglobinemia in rats, cats and dogs. Although species differences in methemoglobin reductase activity in vitro were reported [Stolk et al. 1966: Biochem Pharmacol. 15, 343-351], there is no information on species differences of chemical-induced methemoglobinemia in vivo, including m-toluidine.
Table 1: Methemoglobin induction in experimental animals
Route / Animals / Dose / Methemoglobin ratio / References
oral / rat / 200 mg/kg bw / 36.4 % / Senczuk und Rucinska 1984
dermal / rat / 2.5 -12.5 mg/ml / 40 % / Senczuk und Rucinska 1984
dermal / rat / 700 mg/kg bw / 32.6 % / Vasilenko et al 1977
i.v. / cat / 26.79 mg/kg bw / 60.2 % / McClean et al 1967, 1969
i.v. / dog / 111.1 mg/kg bw / 56 % / Kiese 1963
DISTRIBUTION and METABOLISM
For m-toluidine as a small molecule with the given water solubility, a wide distribution in the body is expected. Based on the log Pow of 1.4 a distribution into the cells is likely. This assumption is confirmed by the variety of effects shown in the oral repeated dose toxicity study: male and female rats received by gavage doses of up to and including 300 mg/kg bw/day over a period of at least 4 weeks resulting in body weight gain reduction from the first week and macroscopic and microscopic changes in liver, kidney and spleen and in blood chemistry data (MHLW 1995) due to hematotoxicity of m-toluidine.
Based on the negative results in genotoxicity in-vitro tests (MHLW 1995b and 2002: Ames test, and Test for Chromosome aberrations, with and without metabolic activation) it is concluded that DNA reactive metabolites of m-toluidine will most probably not be generated in mammals in the course of hepatic transformation.
Furthermore, Cheever, 1980 (cited by UNEP 2003)investigated urinary excretion and metabolism after single oral administration of 500 mg m-toluidine to rats and reported that only 2.5 % of unchanged compound was recovered from urine and as main metabolites 2-amino-4-methyl-phenol and 4-amio-2-methyl-phenol were identified in the urine after hydrolysis.
ACCUMULATION
In general, substances with log Pow of 3 or less would be unlikely to accumulate in fatty tissue.
EXCRETION
On the basis of the molecular structure (Ammonium group), the molecular size and the water solubility excretion into the urine seems to be the main route of elimination. This assumption is supported by the findings of Cheever 1980 identifying 2.5 % m-toluidine in the unchanged form and the metabolites 2-amino-4-methyl-phenol and 4-amino-2-methyl-phenol in rat urine.
SUMMARY
In summary, m-toluidine is assumed to be absorbed following inhalation, oral, or dermal exposure, readily distributed in the body and metabolized. Accumulation is not expected. Urinary excretion is assumed to be the main elimination route.
REFERENCES
Cheever K et al. 1980: Metabolism of ortho-, meta-, and para-toluidine in the adult male rats Toxicol Appl Pharmacol 56, 361-369
DuPont De Nemours, 1980a: Oral LD50 Test in rats of benzenamine, 3-methyl, NTIS Document OTS0557168
DuPont De Nemours, 1980b: Skin Irritation Test of benzenamine, 3-methyl in rabbits, NTIS- OTS0557170
Kiese M 1963: Effects of certain substituents upon the N-oxidation of aniline in vivo, Naunyn Schmiedeberg’s Arch Exp Pathol and Pharmacol 244, 387-404 cited by UNEP 2003
McLean S et al, 1967: Methaemoglobin formation induced by aromatic amines and amides J Pharm Pharmac 19, 146-154
McLean S et al 1969: Methaemoglobin formation by aromatic amines J Pharm Pharmac 21, 441-450
Ministry of Health, Labour and Welfare (MHLW) 1995a: m-Toluidine, Testing reports on environmental chemicals Vol 2, 79-81, 83 -97, 527-532
Ministry of Health, Labour and Welfare (MHLW) 1995: m-Toluidine, Testing reports on environmental chemicals Vol 2, 79-81, 99 -102, 539-542
Ministry of Health, Labour and Welfare (MHLW) 2002: m-Toluidine, Testing reports on environmental chemicals Vol 9, 195-201, 590-593
Senczuk W and Rucinska H 1984: Bromat Chem Toxsykol. 17, 241-243 cited by UNEP, 2003
United Nations Environmental Program – Chemical Branch (UNEP) 2003: OECD Screening Information Data Set (SIDS) for High Production Volume Chemicals: m-Toluidine
Vasilenko NM et al. 1977: Deposited Doc. ISS Viniti 4035-4077 cited by UNEP, 2003
Vohr HW 2009: m-Toluidine, local Lymphnode Assay in mice (LLNA/IMDS)Report No. AT05698, Bayer Schering Pharma AG
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
